Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Revenue (2021 - 2024)

Allogene Therapeutics (ALLO) has disclosed Revenue for 4 consecutive years, with $22000.0 as the latest value for Q1 2024.

  • Quarterly Revenue fell 26.67% to $22000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $22000.0 through Dec 2024, down 76.84% year-over-year, with the annual reading at $22000.0 for FY2024, 76.84% down from the prior year.
  • Revenue hit $22000.0 in Q1 2024 for Allogene Therapeutics, up from $21000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $75.7 million in Q4 2021 to a low of $21000.0 in Q4 2023.
  • Historically, Revenue has averaged $8.8 million across 4 years, with a median of $30000.0 in 2023.
  • Biggest YoY gain for Revenue was 45.45% in 2022; the steepest drop was 99.97% in 2022.
  • Year by year, Revenue stood at $75.7 million in 2021, then crashed by 99.97% to $26000.0 in 2022, then dropped by 19.23% to $21000.0 in 2023, then rose by 4.76% to $22000.0 in 2024.
  • Business Quant data shows Revenue for ALLO at $22000.0 in Q1 2024, $21000.0 in Q4 2023, and $22000.0 in Q3 2023.